title: Effectiveness of chelation therapy with time after acute vanadium intoxication.
abstract: The effect of increasing the time interval between vanadium exposure and chelation therapy was studied in male Swiss mice. The following chelating or reducing agents were administered i.p. at 0, 0.5, 2 and 8 h after i.p. administration of 0.16 mmol kg-1 sodium metavanadate: ascorbic acid, deferoxamine mesylate (DFOA) and 4,5-dihydroxy-1,3-benzene-disulphonic acid (Tiron). These agents were given at doses equal to one-quarter of their respective LD50 values. Daily elimination of vanadium into urine and faeces was determined for four days. The excretion of vanadium was especially rapid in the first 24 h. Treatment with Tiron increased significantly the urinary elimination of vanadium in all four groups during Day 1, whereas DFOA significantly increased the faecal excretion during the same period. Treatment with DFOA or Tiron resulted in a significant decrease in the concentration of vanadium in the kidney four days after sodium metavanadate administration. The magnitude of the increased elimination of vanadium, as well as the decreased tissue concentration of the metal, was remarkably attenuated by increasing the time interval between vanadium injection and administration of the chelators.
authors.affiliation: Laboratory of Toxicology and Biochemistry, Faculty of Medicine, University of Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Gómez
authors.forename: J L
authors.initials: JL
authors.lastname: Domingo
authors.forename: J M
authors.initials: JM
authors.lastname: Llobet
authors.forename: J L
authors.initials: JL
authors.lastname: Paternain
mesh_terms: D014013:1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt / Q000627:therapeutic use; D000818:Animals; D001205:Ascorbic Acid / Q000627:therapeutic use; D002614:Chelating Agents / Q000627:therapeutic use*; D003676:Deferoxamine / Q000627:therapeutic use; D005243:Feces / Q000032:analysis; D008297:Male; D051379:Mice; D013997:Time Factors; D014018:Tissue Distribution; D014639:Vanadium / Q000493:pharmacokinetics / Q000633:toxicity* / Q000652:urine
chemical_list: D002614:Chelating Agents; D014639:Vanadium; D014013:1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; D003676:Deferoxamine; D001205:Ascorbic Acid